The company recently completed an open label, multicenter, randomized trial in 90 patients with untreated advanced NSCLC. The study evaluated Biothera's immunotherapeutic drug candidate, Imprime PGG®, with cetuximab (Erbitux®), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone.
Biothera previously announced that the study had met its primary endpoint with a statistically significant improvement in objective response rate in the treatment group. Researchers noted that a subset of subjects who tested positive for a biomarker linked to the ability of their immune cells to bind and respond to Imprime PGG showed further improvement in response rates and a six-month improvement in overall survival.
For more information, visit our website at www.biothera.com/pharma. About Biothera, the Immune Health CompanyBiothera is a U.S. biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight cancer.
Keywords for this news article include: Drugs, Biothera, Oncology, Chemotherapy, Lung Neoplasms, Gastroenterology, Non-Small Cell Lung Cancer, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- 5 Notable Hispanic Technology Executives
- Top Hispanic Tech Companies Push for the Top
- Tesla's Alt-Energy Future Aims for Massive Lithium-Ion Battery Production
- Rand Paul Tops Presidential Straw Poll at Conservative PAC Conference
- Russia, Crimea Discuss Referendum
- China Urges Malaysia Flight Emergency Response
- New Chat App, Yik Yak, Causes Problems for Students
- Gas Prices May Jump from Calif. Emissions Law
- Obama Meets with Ukraine Prime Minister Wednesday
- Visa, MasterCard Team Up to Focus on Payment Security